Berberine attenuates doxorubicininduced cardiotoxicity in mice

Journal of International Medical Research

Volumn 39, Issue 5, 2011, Pages 1720-1727

  Zhao, Xiaoyan ^a   Zhang, J ^b   Tong, N ^a   Liao, X ^a   Wang, E ^a   Li, Z ^a   Luo, Y ^a   Zuo, H ^a  

^a SOUTHWEST UNIVERSITY   (China)

^b CHONGQING THREE GORGES UNIVERSITY   (China)

Author keywords

Berberine; Cardiotoxicity; Doxorubicin; Electrocardiogram; Mice

Indexed keywords

BERBERINE; DOXORUBICIN; LACTATE DEHYDROGENASE; CARDIOTONIC AGENT; CARDIOTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ELECTROCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE INJURY; HEART PROTECTION; HISTOPATHOLOGY; MOUSE; NONHUMAN; QRS PROLONGATION; TREATMENT DURATION; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DRUG ANTAGONISM; FEMALE; HEART MUSCLE; MALE; PATHOLOGY; RANDOMIZATION; WEIGHT GAIN;

ANIMALS; BERBERINE; CARDIOTONIC AGENTS; CARDIOTOXINS; DOXORUBICIN; ELECTROCARDIOGRAPHY; FEMALE; L-LACTATE DEHYDROGENASE; MALE; MICE; MICE, INBRED BALB C; MYOCARDIUM; RANDOM ALLOCATION; WEIGHT GAIN;

EID: 80155130003     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900514     Document Type: Article

References (25)

1. Carvalho C, Santos RX, Cardoso S, et al: Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 2009; 16: 3267-3285.
2. Silber JH, Barber G: Doxorubicin-induced cardiotoxicity. N Engl J Med 1995; 333: 1359-1360.
3. Doroshow JH: Doxorubicin-induced cardiac toxicity. N Engl J Med 1991; 324: 843-845.
4. Takemura G, Fujiwara H: Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007; 49: 330-352.
5. Kotamraju S, Konorev EA, Joseph J, et al: Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem 2000; 275: 33585-33592.
6. Della Torre P, Imondi AR, Bernardi C, et al: Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel. Cancer Chemother Pharmacol 1999; 44: 138-142.
7. Li L, Takemura G, Li Y, et al: Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 2006; 113: 535-543.
8. Wang Y, Huang Y, Lam KS, et al: Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase. Cardiovasc Res 2009; 82: 484-492.
9. Affuso F, Mercurio V, Fazio V, et al: Cardiovascular and metabolic effects of Berberine. World J Cardiol 2010; 2: 71-77.
10. Danesi R, Del Tacca M, Soldani G: Measurement of the S alpha T segment as the most reliable electrocardiogram parameter for the assessment of adriamycin-induced cardiotoxicity in the rat. J Pharmacol Methods 1986; 16: 251-259.
11. Matuszczyk A, Petersenn S, Bockisch A, et al: Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 2008; 40: 210-213.
12. Minotti G, Menna P, Salvatorelli E, et al: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185-229.
13. Swain SM, Whaley FS, Ewer MS: Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-2879.
14. Cardinale D, Colombo A, Lamantia G, et al: Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010; 55: 213-220.
15. Zhang Y, Li X, Zou D, et al: Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 2008; 93: 2559-2565.
16. Yin J, Gao Z, Liu D, et al: Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab 2008; 294: E148-E156.
17. Zeng XH, Zeng XJ, Li YY: Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardio-myopathy. Am J Cardiol 2003; 92: 173-176.
18. Liu JC, Chan P, Chen YJ, et al: The antihypertensive effect of the berberine derivative 6-protoberberine in spontaneously hypertensive rats. Pharmacology 1999; 59: 283-289.
19. Herman EH, Zhang J, Chadwick DP, et al: Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. Cancer Chemother Pharmacol 2000; 45: 329-334.
20. Tallaj JA, Franco V, Rayburn BK, et al: Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant 2005; 24: 2196-2201.
21. Simmons A, Vacek JL, Meyers D: Anthracyclineinduced cardiomyopathy. Postgrad Med 2008; 120: 67-72.
22. Hazari MS, Haykal-Coates N, Winsett DW, et al: Continuous electrocardiogram reveals differences in the short-term cardiotoxic response of Wistar-Kyoto and spontaneously hypertensive rats to doxorubicin. Toxicol Sci 2009; 110: 224-234.
23. Garba IH, Ubom GA: Total serum lactate dehydrogenase activity in acute Plasmodium falciparum malaria infection. Singapore Med J 2005; 46: 632-634.
24. Zhao XY, Li GY, Liu Y, et al: Resveratrol protects against arsenic trioxide-induced cardiotoxicity in vitro and in vivo. Br J Pharmacol 2008; 154: 105-113.
25. Peng X, Chen B, Lim CC, et al: The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. Mol Interv 2005; 5: 163-171.